1. Introduction {#sec1}
===============

*Chryseobacterium indologenes* is nonmotile, catalase-positive, oxidase-positive, indole-positive, non-glucose-fermenting Gram-negative bacilli. It is not a component of human flora although it is widely distributed in nature.*C. indologenes* is a rare organism that has been reported to cause infections mostly in hospitalised patients with severe underlying diseases \[[@B1], [@B2]\]. The appropriate antibiotic choice is challenging as the organism shows resistance to multiple antibiotics. This report describes a case of*C. indologenes* nosocomial septicemia in an infant with congenital heart disease and reviews previously reported infections by*C. indologenes* in pediatric age group.

2. Case Report {#sec2}
==============

A three-month-old female infant born at term by vaginal delivery presented to our hospital with cough and irritability. Atrioventricular septal defect was diagnosed when she was 15-day-old and she was on followup by cardiology clinic. On admission she had tachypnea and cardiac murmur on auscultation. All the other physical examinations of her were unremarkable. A complete blood count showed a white blood cell (WBC) count of 11.000/mm³ with 60% lymphocytes and C-reactive protein (CRP) level was 1 mg/L (range, 0--8 mg/L). Serum biochemical investigations were in normal range. Chest X-ray showed hyperinflation and peribronchiolar wall thickening. She was hospitalized for acute community acquired pneumonia and ampicillin sulbaktam plus clarithromycin was initiated. Respiratory virus multiplex polymerase chain reaction (PCR) obtained at admission revealed respiratory syncytial virus. Blood culture was performed since her clinical condition deteriorated and fever occurred on day 6.*Candida albicans* was isolated on blood culture and she was treated for nosocomial candidemia with caspofungin for 21 days, serial blood cultures were negative, and she was discharged in a good clinical condition. Four days after discharge, she was rehospitalized for the diagnosis of nosocomial pneumonia and empirically treated with meropenem and caspofungin intravenously. Blood and urine cultures showed no growth. During the hospitalization, fever up to 39°C occurred. She had a central venous catheter and her remaining physical examination was unremarkable. Laboratory investigations were as follows: hemoglobin 9.5 mg/dL, WBC 22.200/mm^3^ with 70% neutrophil, platelets 516.000/mm^3^, and CRP 21.1 mg/L. Chest X-ray showed no new infiltration and also abdominal ultrasonography and echocardiography did not show any infectious focus. Central venous catheter was removed because of obstruction. Specimen from peripheral blood culture yielded yellow colonies on blood agar ([Figure 1](#fig1){ref-type="fig"}).*C. indologenes* was identified by conventional methods and VITEK 2 ID-AST (bioMérieux, France) automatized system. Antimicrobial susceptibility testing of the organism revealed resistance to amikacin, gentamicin, ceftazidime, cefepime, piperacillin tazobactam, cefoperazone sulbactam, imipenem, meropenem, colistin, tetracycline, and ciprofloxacin and was susceptible to only trimethoprim sulfamethoxazole (TMP-SMX). TMP-SMX (20 mg/kg/day, intravenously) was initiated. Her fever resolved and blood culture became negative after 48 hours of the treatment. The antibiotic treatment was given for a course of 21 days. After discharge she was operated on in another hospital. She has been on followup in a good clinical condition for seven months.

3. Discussion {#sec3}
=============

The genus*Chryseobacterium*(previously*Flavobacterium)* belongs to the family Flavobacteriaceae that are ubiquitous in nature and are inhabitants of soil and water and can be recovered from a variety of foods. They can be found in municipal water supplies despite adequate chlorination and can be recovered from the hospital environment \[[@B3]\]. Contamination of the medical devices containing water (respirators, intubation tubes, humidifiers, etc.) in hospital settings may lead to serious infections.*C. indologenes* colonies usually form a dark-yellow pigment in culture as a result of the production of the pigment flexirubin.

*C. indologenes* is a rare cause of human disease.*C. indologenes*was first isolated from a clinical specimen in 1993 from the tracheal aspirate of a patient with ventilator-associated pneumonia \[[@B4]\].*Chryseobacteria* represent only 0.27% (50 of 18,569) of the processed nonfermentative Gram-negative bacilli and 0.03% (50 of 155,811) of all bacterial isolates collected by the SENTRY Surveillance Program during the 5-year period 1997 to 2001 \[[@B5]\].*C. indologenes*infections have been shown as a cause for a variety of invasive infections especially in patients with risk factors, such as intravascular catheter-related bacteremia, bacteremia associated with malignancy and neutropenia, nosocomial pneumonia, cellulitis, meningitis, peritonitis, and surgical wound infections \[[@B2], [@B6]--[@B11]\]. A total of 14 cases of*C. indologenes* infections in pediatric age group were found in English literature. The diagnoses of the reported cases were bacteremia (six cases), meningitis (five cases), ventilator-associated pneumonia (two cases), and lumboperitoneal shunt infection (one case). Ten of 14 patients had medical devices, 12 of 14 patients had comorbidity, and 12 of 14 patients were ≤2 years old. The summary of cases is presented in [Table 1](#tab1){ref-type="table"}.

*Chryseobacteria* have low pathogenicity and cause infections mostly in hospitalised patients with risk factors including underlying medical illness, age (newborn or elderly) underlying immunocompromising conditions, presence of indwelling intravascular devices, and prolonged exposure to broad-spectrum antibiotics. The present case had congenital heart disease, central venous catheter, and prolonged usage of broad-spectrum antibiotics as risk factors.

The choice of an effective drug for the empirical treatment of infections due to*C. indologenes*is difficult as the organism has a limited spectrum of antimicrobial sensitivity.*Chryseobacterium* organisms produce *β*-lactamases and are resistant to most *β*-lactam drugs, including the carbapenems and aztreonam \[[@B3]\]. In a study that included 215*C. indologenes*isolates, TMP-SMX and cefoperazone-sulbactam remained the most active agent especially for bloodstream infections. Authors concluded that, after introduction of colistin and tigecycline usage because of emerging resistant pathogens, the prevalence of*C. indologenes* infection increased \[[@B12]\]. According to the results of the SENTRY Antimicrobial Surveillance Program, the most active agents against*C. indologenes* are the newer quinolones (garenoxacin, gatifloxacin, and levofloxacin, ≥95% susceptibility) and TMP-SMX (95% susceptibility), followed by piperacillin-tazobactam (90% susceptibility). Ciprofloxacin, cefepime, ceftazidime, piperacillin, and rifampin showed reasonable activity (85% susceptibility) \[[@B5]\]. On the contrary, other *β*-lactams, aminoglycosides, chloramphenicol, linezolid, and glycopeptides are not appropriate for treating infections caused by this organism. According to more recent report it was suggested that only newer fluoroquinolones and TMP-SMX could possibly represent the most appropriate antimicrobial agents \[[@B1]\].

In conclusion*C. indologenes* may cause nosocomial septicemia in infants with the risk factors as underlying prolonged hospitalization, prolonged usage of broad-spectrum antibiotics, and having comorbidity. The microorganism may have resistance to most antimicrobial agents empirically prescribed for nosocomial Gram-negative infections. For this reason, when*C. indologenes* is isolated in normally sterile sites of body, antimicrobial susceptibility test results are important to assure appropriate antibiotic coverage. This case report demonstrated that TMP-SMX may be the only appropriate antimicrobial agent to treat bacteremia caused by this pathogen.
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###### 

Demographic and clinical characteristics of *Chryseobacterium  indologenes* infections in pediatric patients.

  Patient no.   Reference/year                         Age/sex   Comorbidity                                                                  Medical devices present      Clinical syndrome                        Antibiotic                                            Outcome
  ------------- -------------------------------------- --------- ---------------------------------------------------------------------------- ---------------------------- ---------------------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------
  1             Hsueh et al., 1996 \[[@B2], [@B6]\]    1 mo/M    Burns                                                                        Ventilator                   Ventilator-associated pneumonia          Ciprofloxacin, cefoxitin, amikacin                    Died (ARDS)
                                                                                                                                                                                                                                                                          
  2             Hsueh et al., 1996 \[[@B2], [@B6]\]    5 mo/F    Neuroblastoma, chemotherapy                                                  Hickman catheter             Bacteremia                               Not stated                                            Recovery without removal of catheter (after 3 days)
                                                                                                                                                                                                                                                                          
  3             Hsueh et al., 1996 \[[@B2], [@B6]\]    1 mo/F    Hepatoblastoma, chemotherapy                                                 Port-A-catheter              Bacteremia                               Not stated                                            Recovery without removal of catheter (after 3 days)
                                                                                                                                                                                                                                                                          
  4             Cascio et al., 2005 \[[@B13]\]         2 y/M     Type 1 diabetes mellitus                                                     Peripheral catheter          Bacteremia                               Ceftriaxone, 10 days                                  Recovery with removal of catheter (afebrile after 2 days)
                                                                                                                                                                                                                                                                          
  5             Al-Tatari et al., 2007 \[[@B14]\]      13 y/M    Congenital hydrocephalus                                                     Lumboperitoneal shunt        Lumboperitoneal shunt infection          TMP-SMX and rifampin (for 14 d after shunt removal)   Recovery 24 h after shunt removal
                                                                                                                                                                                                                                                                          
  6             Bayraktar et al., 2007 \[[@B15]\]      5 mo/M    Down syndrome, operation for atrial septal defect and diaphragmatic hernia   Mechanical ventilation       Bacteremia                               Vancomycin and ofloxacin                              Died
                                                                                                                                                                                                                                                                          
  7             Douvoyiannis et al., 2010 \[[@B16]\]   33 d/F    None                                                                         None                         Bacteremia                               Cefepime, 10 days                                     Recovery (afebrile after a day)
                                                                                                                                                                                                                                                                          
  8             Ceylan et al., 2011 \[[@B17]\]         2 mo/M    Hydrocephaly                                                                 External shunt               Meningitis sepsis                        Ampicillin sulbactam and levofloxacin                 Died (cardiopulmonary arrest)
                                                                                                                                                                                                                                                                          
  9             Calderón et al., 2011 \[[@B8]\]        20 d/M    Congenital heart disease                                                     Mechanical ventilation       Ventilator-associated pneumonia          Piperacillin-tazobactam (14 days)                     Recovery
                                                                                                                                                                                                                                                                          
  10            Kodama et al., 2013 \[[@B18]\]         3 y/F     Acute myeloid leukemia unrelated cord blood stem cell transplantation        Central venous catheter      Catheter-related bloodstream infection   Ciprofloxacin and minocycline                         Recovery with removal of catheter
                                                                                                                                                                                                                                                                          
  11            Ozcan et al., 2013 \[[@B19]\]          6 mo/M    Congenital hydrocephalus, prematurity                                        Ventriculoperitoneal shunt   Meningitis                               TMP-SMX and cefoperazone-sulbactam (14 days)          Recovery with removal of shunt
                                                                                                                                                                                                                                                                          
  12            Hendaus et al., 2013 \[[@B20]\]        8 d/F     None                                                                         None                         Meningitis                               Cefepime (21 days)                                    Recovery (afebrile after 2 days)
                                                                                                                                                                                                                                                                          
  13            Eshwara et al., 2014 \[[@B10]\]        6 d/F     Small for gestational age                                                    None                         Meningitis sepsis                        TMP-SMX (2 weeks) and ciprofloxacin (6 weeks)         Recovery
                                                                                                                                                                                                                                                                          
  14            Olbrich et al., 2014 \[[@B21]\]        11 mo/M   Holoprosencephaly, suboptimal hygienic conditions                            Ventriculoperitoneal shunt   Meningitis                               TMP-SMX and ceftazidime (21 days)                     Recovery (afebrile in 24 h) with complete removal of the cerebrospinal shunt system
                                                                                                                                                                                                                                                                          
  15            This study, 2014                       3 mo/F    Congenital heart disease                                                     Central venous catheter      Bacteremia                               TMP-SMX (21 days)                                     Recovery (afebrile after 2 days)
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